Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62022CN0310

    Case C-310/22: Request for a preliminary ruling from the College van Beroep voor het bedrijfsleven (Netherlands) lodged on 11 May 2022 — Pesticide Action Network Europe (PAN Europe) v College voor de toelating van gewasbeschermingsmiddelen en biociden in the presence of: BASF Nederland BV (BASF)

    OJ C 359, 19.9.2022, p. 22–22 (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    19.9.2022   

    EN

    Official Journal of the European Union

    C 359/22


    Request for a preliminary ruling from the College van Beroep voor het bedrijfsleven (Netherlands) lodged on 11 May 2022 — Pesticide Action Network Europe (PAN Europe) v College voor de toelating van gewasbeschermingsmiddelen en biociden in the presence of: BASF Nederland BV (BASF)

    (Case C-310/22)

    (2022/C 359/23)

    Language of the case: Dutch

    Referring court

    College van Beroep voor het bedrijfsleven

    Parties to the main proceedings

    Applicant: Pesticide Action Network Europe (PAN Europe)

    Defendant: College voor de toelating van gewasbeschermingsmiddelen en biociden

    In the presence of: BASF Nederland BV (BASF)

    Questions referred

    1.

    Does it follow from the second paragraph of Article 4(1) of Regulation 1107/2009, (1) in conjunction with paragraph 3.6.5 of Annex II thereto, that the potential endocrine disrupting properties of an active substance need no longer be assessed during the assessment at national level of an application for authorisation of a plant protection product?

    2.

    If the answer to the first question is in the affirmative, does it mean that the scientific insights and technical knowledge relating to endocrine disrupting properties, which, for example, underpin Regulations 283/2013 (2) and 2018/605, (3) need not be taken into account when assessing the authorisation of a plant protection product? How does that relate to the requirement of Article 29(1)(e) of Regulation 1107/2009 that such an assessment must be conducted on the basis of current scientific and technical knowledge?

    3.

    If the answer to the first question is in the affirmative, how can a non-governmental organisation such as the appellant be said to have an effective remedy under Article 47 of the Charter to refer the approval of an active substance to a court of law?

    4.

    If the answer to the first question is in the negative, does it mean that, when assessing an application for authorisation, the state of scientific and technical knowledge about that endocrine disrupting property at that time is decisive?


    (1)  Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC (OJ 2009 L 309, p. 1).

    (2)  Commission Regulation (EU) No 283/2013 of 1 March 2013 setting out the data requirements for active substances, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market (OJ 2013 L 93, p. 1).

    (3)  Commission Regulation (EU) 2018/605 of 19 April 2018 amending Annex II to Regulation (EC) No 1107/2009 by setting out scientific criteria for the determination of endocrine disrupting properties (OJ 2018 L 101, p. 33).


    Top